each human gene is encoded as deoxyribonucleic acid dna,which takes the shape of a double helix.each in that helix consists of two chemically joined nucleotides.sequences of dna nucleotides contain the information necessary to create strings of amino acids used to build proteins in the body.the nucleotides that code for amino acids are exons,and those that do not are introns.scientists can extract dna from cells to isolate specific segments for study.they can also synthetically create strands of nucleotides known as composite dna cdna.cdna contains only the exons that occur in dna,omitting the intervening introns.
respondent myriad genetics,myriad,obtained several patents after discovering the precise location and sequence of the and genes,mutations of which can dramatically increase the risk of breast and ovarian cancer.this knowledge allowed myriad to determine the genes typical nucleotide sequence,which,in turn,enabled it to develop medical tests useful for detecting mutations in these genes in a particular patient to assess the patient cancer risk.if valid,myriad patents would give it the exclusive right to isolate an individual and genes,and would give myriad the exclusive right to synthetically create brca cdna.petitioners filed suit,seeking a declaration that myriad patents are invalid under.as relevant here,the district court granted summary judgment to petitioners,concluding that myriad claims were invalid because they covered products of nature.the federal circuit initially reversed,but on remand in light of mayo collaborative services prometheus laboratories,the circuit found both isolated dna and cdna patent eligible.
held a naturally occurring dna segment is a product of nature and not patent eligible merely because it has been isolated,but cdna is patent eligible because it is not naturally occurring.
a the patent act permits patents to be issued to w hoever invents or discovers any new and useful composition of matter,but laws of nature,natural phenomena,and abstract ideas are basic tools of scientific and technological work that lie beyond the domain of patent protection,mayo,supra,at.the rule against patents on naturally occurring things has limits,however.patent protection strikes a delicate balance between creating incentives that lead to creation,invention,and discovery and imped ing the flow of information that might permit,indeed spur,invention.at.this standard is used to determine whether myriad patents claim a new and useful composition of matter,or claim naturally occurring phenomena.
b myriad dna claim falls within the law of nature exception.myriad principal contribution was uncovering the precise location and genetic sequence of the and genes.diamond chakrabarty,is central to the inquiry whether such action was new with markedly different characteristics from any found in nature,at.myriad did not create or alter either the genetic information encoded in the and genes or the genetic structure of the dna.it found an important and useful gene,but groundbreaking,innovative,or even brilliant discovery does not by itself satisfy the inquiry.see funk brothers seed kalo inoculant.finding the location of the and genes does not render the genes patent eligible new composition s of matter,myriad patent descriptions highlight the problem with its claims they detail the extensive process of discovery,but extensive effort alone is insufficient to satisfy demands.myriad claims are not saved by the fact that isolating dna from the human genome severs the chemical bonds that bind gene molecules together.the claims are not expressed in terms of chemical composition,nor do they rely on the chemical changes resulting from the isolation of a particular dna section.instead,they focus on the genetic information encoded in the and genes.finally,myriad argues that the patent and trademark office past practice of awarding gene patents is entitled to deference,citing ag supply,pioneer int l,a case where congress had endorsed a pto practice in subsequent legislation.there has been no such endorsement here,and the united states argued in the federal circuit and in this court that isolated dna was not patent eligible under.
c cdna is not a product of nature,so it is patent eligible under.cdna does not present the same obstacles to patentability as naturally occurring,isolated dna segments.its creation results in an molecule,which is not naturally occurring.its order of the exons may be dictated by nature,but the lab technician unquestionably creates something new when introns are removed from a dna sequence to make cdna.
d this case,it is important to note,does not involve method claims,patents on new applications of knowledge about the and genes,or the patentability of dna in which the order of the naturally occurring nucleotides has been altered.
affirmed in part and reversed in part.
thomas,delivered the opinion of the court,in which roberts,and kennedy,ginsburg,breyer,alito,sotomayor,and kagan,joined,and in which scalia,joined in part.scalia,filed an opinion concurring in part and concurring in the judgment.
opinion of the court 
notice this opinion is subject to formal revision before publication in the preliminary print of the united states reports.readers are requested to notify the reporter of decisions,supreme court of the united states,washington,of any typographical or other formal errors,in order that corrections may be made before the preliminary print goes to press.
association for molecular pathology,et,petitioners myriad genetics,et.
on writ of certiorari to the united states court of appeals for the federal circuit 
justice thomas delivered the opinion of the court.
respondent myriad genetics,myriad,discovered the precise location and sequence of two human genes,mutations of which can substantially increase the risks of breast and ovarian cancer.myriad obtained a number of patents based upon its discovery.this case involves claims from three of them and requires us to resolve whether a naturally occurring segment of deoxyribonucleic acid dna is patent eligible under by virtue of its isolation from the rest of the human genome.we also address the patent eligibility of synthetically created dna known as complementary dna cdna,which contains the same information found in a segment of natural dna but omits portions within the dna segment that do not code for proteins.for the reasons that follow,we hold that a naturally occurring dna segment is a product of nature and not patent eligible merely because it has been isolated,but that cdna is patent eligible because it is not naturally occurring.we,therefore,affirm in part and reverse in part the decision of the united states court of appeals for the federal circuit.
genes form the basis for hereditary traits in living organisms.see generally association for molecular pathology united states patent and trademark office,supp,sdny.the human genome consists of approximately genes packed into pairs of chromosomes.each gene is encoded as dna,which takes the shape of the familiar double helix that doctors james watson and francis crick first described in.each in the dna helix consists of two chemically joined nucleotides.the possible nucleotides are adenine a,thymine t,cytosine c,and guanine g,each of which binds naturally with another nucleotide a pairs with t c pairs with g.the nucleotide are chemically connected to a backbone that forms the outside framework of the dna helix.sequences of dna nucleotides contain the information necessary to create strings of amino acids,which in turn are used in the body to build proteins.only some dna nucleotides,however,code for amino acids these nucleotides are known as exons.nucleotides that do not code for amino acids,in contrast,are known as introns.
creation of proteins from dna involves two principal steps,known as transcription and translation.in transcription,the bonds between dna nucleotides separate,and the dna helix unwinds into two single strands.a single strand is used as a template to create a complementary ribonucleic acid rna strand.the nucleotides on the dna strand pair naturally with their counterparts,with the exception that rna uses the nucleotide base uracil u instead of thymine t.transcription results in a single strand rna molecule,known as,whose nucleotides form an inverse image of the dna strand from which it was created.still contains nucleotides corresponding to both the exons and introns in the dna molecule.the is then naturally spliced by the physical removal of the introns.the resulting product is a strand of rna that contains nucleotides corresponding only to the exons from the original dna strand.the strand is known as messenger rna mrna,which creates amino acids through translation.in translation,cellular structures known as ribosomes read each set of three nucleotides,known as codons,in the mrna.each codon either tells the ribosomes which of the possible amino acids to synthesize or provides a stop signal that ends amino acid production.
dna informational sequences and the processes that create mrna,amino acids,and proteins occur naturally within cells.scientists can,however,extract dna from cells using well known laboratory methods.these methods allow scientists to isolate specific segments of dna for instance,a particular gene or part of a gene which can then be further studied,manipulated,or used.it is also possible to create dna synthetically through processes similarly well known in the field of genetics.one such method begins with an mrna molecule and uses the natural bonding properties of nucleotides to create a new,synthetic dna molecule.the result is the inverse of the mrna inverse image of the original dna,with one important distinction because the natural creation of mrna involves splicing that removes introns,the synthetic dna created from mrna also contains only the exon sequences.this synthetic dna created in the laboratory from mrna is known as complementary dna cdna.
changes in the genetic sequence are called mutations.mutations can be as small as the alteration of a single nucleotide a change affecting only one letter in the genetic code.such changes can produce an entirely different amino acid or can end protein production altogether.large changes,involving the deletion,rearrangement,or duplication of hundreds or even millions of nucleotides,can result in the elimination,misplacement,or duplication of entire genes.some mutations are harmless,but others can cause disease or increase the risk of disease.as a result,the study of genetics can lead to valuable medical breakthroughs.
this case involves patents filed by myriad after it made one such medical breakthrough.myriad discovered the precise location and sequence of what are now known as the and genes.mutations in these genes can dramatically increase an individual risk of developing breast and ovarian cancer.the average american woman has a to risk of developing breast cancer,but for women with certain genetic mutations,the risk can range between and percent for breast cancer and between and percent for ovarian cancer.before myriad discovery of the and genes,scientists knew that heredity played a role in establishing a woman risk of developing breast and ovarian cancer,but they did not know which genes were associated with those cancers.
myriad identified the exact location of the and genes on chromosomes and.chromosome has approximately million nucleotides,and chromosome has approximately million.association for molecular pathology united states patent and trademark office,ca fed.within those chromosomes,the and genes are each about nucleotides long.if just exons are counted,the gene is only about nucleotides long for the gene,that number is about.ibid.knowledge of the location of the and genes allowed myriad to determine their typical nucleotide sequence that information,in turn,enabled myriad to develop medical tests that are useful for detecting mutations in a patient and genes and thereby assessing whether the patient has an increased risk of cancer.
once it found the location and sequence of the and genes,myriad sought and obtained a number of patents.nine composition claims from three of those patents are at issue in this case see,at,and noting composition claims.claims,and from the patent are representative.the first claim asserts a patent on a n isolated dna coding for a polypeptide,which has the amino acid sequence set forth in seq id no.app.seq id no sets forth a list of amino acids that the typical gene encodes.see,at.put differently,claim asserts a patent claim on the dna code that tells a cell to produce the string of amino acids listed in seq id no.
claim of the patent operates similarly.it claims t he isolated dna of claim,wherein said dna has the nucleotide sequence set forth in seq id no.at.like seq id no,seq id no sets forth a long list of data,in this instance the sequence of cdna that codes for the amino acids listed in claim.importantly,seq id no lists only the cdna exons in the gene,rather than a full dna sequence containing both exons and introns.see,at stating that seq id no molecule type is cdna as a result,the federal circuit recognized that claim asserts a patent on the cdna nucleotide sequence listed in seq id no,which codes for the typical gene,at,at moore,concurring in part,at bryson,concurring in part and dissenting in part.
claim of the patent claims a subset of the data in claim.in particular,it claims a n isolated dna having at least nucleotides of the dna of claim.app.the practical effect of claim is to assert a patent on any series of nucleotides that exist in the typical gene.because the gene is thousands of nucleotides long,even genes with substantial mutations are likely to contain at least one segment of nucleotides that correspond to the typical gene.similarly,claim of the patent claims a n isolated dna having at least nucleotides of the dna of claim.ibid.this claim operates similarly to claim,except that it references the claim.the remaining claims at issue are similar,though several list common mutations rather than typical and sequences.see ibid.claim of the patent,at claim of the patent,at claims,and of the patent.
myriad patents would,if valid,give it the exclusive right to isolate an individual and genes or any strand of or more nucleotides within the genes by breaking the covalent bonds that connect the dna to the rest of the individual genome.the patents would also give myriad the exclusive right to synthetically create brca cdna.in myriad view,manipulating brca dna in either of these fashions triggers its right to exclude others from making its patented composition of matter under the patent act.a see also a w hoever without authority makes any patented invention infringes the patent 
but isolation is necessary to conduct genetic testing,and myriad was not the only entity to offer brca testing after it discovered the genes.the university of pennsylvania genetic diagnostic laboratory gdl and others provided genetic testing services to women.petitioner harry ostrer,then a researcher at new york university school of medicine,routinely sent his patients dna samples to gdl for testing.after learning of gdl testing and ostrer activities,myriad sent letters to them asserting that the genetic testing infringed myriad patents.app.ostrer letter.in response,gdl agreed to stop testing and informed ostrer that it would no longer accept patient samples.myriad also filed patent infringement suits against other entities that performed brca testing,resulting in settlements in which the defendants agreed to cease all allegedly infringing activity,at.myriad,thus,solidified its position as the only entity providing brca testing.
some years later,petitioner ostrer,along with medical patients,advocacy groups,and other doctors,filed this lawsuit seeking a declaration that myriad patents are invalid under.supp,at.citing this court decision in medimmune,genentech,the district court denied myriad motion to dismiss for lack of standing.association for molecular pathology united states patent and trademark office,supp,sdny.the district court then granted summary judgment to petitioners on the composition claims at issue in this case based on its conclusion that myriad claims,including claims related to cdna,were invalid because they covered products of nature.supp,at.the federal circuit reversed,association for molecular pathology united states patent and trademark office,and this court granted the petition for certiorari,vacated the judgment,and remanded the case in light of mayo collaborative services prometheus laboratories.see association for molecular pathology myriad genetics.
on remand,the federal circuit affirmed the district court in part and reversed in part,with each member of the panel writing separately.all three judges agreed that only petitioner ostrer had standing.they reasoned that myriad actions against him and his stated ability and willingness to begin and testing if myriad patents were invalidated were sufficient for article iii standing,at,at opinion of moore,at opinion of bryson.
with respect to the merits,the court held that both isolated dna and cdna were patent eligible under.the central dispute among the panel members was whether the act of isolating dna separating a specific gene or sequence of nucleotides from the rest of the chromosome is an inventive act that entitles the individual who first isolates it to a patent.each of the judges on the panel had a different view on that question.judges lourie and moore agreed that myriad claims were patent eligible under but disagreed on the rationale.judge lourie relied on the fact that the entire dna molecule is held together by chemical bonds and that the covalent bonds at both ends of the segment must be severed in order to isolate segments of dna.this process technically creates new molecules with unique chemical compositions.see,at isolated dna is a portion of a larger,natural dna molecule.isolated dna has been cleaved,had covalent bonds in its backbone chemically severed or synthesized to consist of just a fraction of a naturally occurring dna molecule judge lourie found this chemical alteration to be dispositive,because isolating a particular strand of dna creates a nonnaturally occurring molecule,even though the chemical alteration does not change the quality of the dna.see,at the claimed isolated dna molecules are distinct from their natural existence as portions of larger entities,and their informational content is irrelevant to that fact.we recognize that biologists may think of molecules in terms of their uses,but genes are in fact materials having a chemical nature accordingly,he rejected petitioners argument that isolated dna was ineligible for patent protection as a product of nature.
judge moore concurred in part but did not rely exclusively on judge lourie conclusion that chemically breaking covalent bonds was sufficient to render isolated dna patent eligible,at to the extent the majority rests its conclusion on the chemical differences between naturally occurring and isolated dna breaking the covalent bonds,i can not agree that this is sufficient to hold that the claims to human genes are directed to patentable subject matter instead,judge moore also relied on the united states patent and trademark office pto practice of granting such patents and on the reliance interests of patent holders,at.however,she acknowledged that her vote might have come out differently if she were deciding this case on a blank canvas.ibid.
finally,judge bryson concurred in part and dissented in part,concluding that isolated dna is not patent eligible.as an initial matter,he emphasized that the breaking of chemical bonds was not dispositive t here is no magic to a chemical bond that requires us to recognize a new product when a chemical bond is created or broken.at.instead,he relied on the fact that t he nucleotide sequences of the claimed molecules are the same as the nucleotide sequences found in naturally occurring human genes.at.judge bryson then concluded that genetic structural similarity dwarfs the significance of the structural differences between isolated dna and naturally occurring dna,especially where the structural differences are merely ancillary to the breaking of covalent bonds,a process that is itself not inventive.ibid.moreover,judge bryson gave no weight to the pto position on patentability because of the federal circuit position that the pto lacks substantive rulemaking authority as to issues such as patentability.at.
although the judges expressed different views concerning the patentability of isolated dna,all three agreed that patent claims relating to cdna met the patent eligibility requirements of,at,and recognizing that some patent claims are limited to cdna and that such claims are patent eligible under,at moore,concurring in part,at bryson,concurring in part and dissenting in part cdna can not be isolated from nature,but instead must be created in the laboratory because the introns that are found in the native gene are removed from the cdna segment we granted certiorari.
section of the patent act provides 
whoever invents or discovers any new and useful composition of matter,or any new and useful improvement thereof,may obtain a patent therefor,subject to the conditions and requirements of this title.
we have long held that this provision contains an important implicit exception laws of nature,natural phenomena,and abstract ideas are not patentable.mayo,at slip,at internal quotation marks and brackets omitted.rather,they are the basic tools of scientific and technological work that lie beyond the domain of patent protection,at slip,at.as the court has explained,without this exception,there would be considerable danger that the grant of patents would tie up the use of such tools and thereby inhibit future innovation premised upon them.at slip,at.this would be at odds with the very point of patents,which exist to promote creation.diamond chakrabarty,products of nature are not created,and manifestations of nature are free to all men and reserved exclusively to none 
the rule against patents on naturally occurring things is not without limits,however,for all inventions at some level embody,use,reflect,rest upon,or apply laws of nature,natural phenomena,or abstract ideas,and too broad an interpretation of this exclusionary principle could eviscerate patent law.at slip,at.as we have recognized before,patent protection strikes a delicate balance between creating incentives that lead to creation,invention,and discovery and imped ing the flow of information that might permit,indeed spur,invention.at slip,at.we must apply this standard to determine whether myriad patents claim any new and useful composition of matter,or instead claim naturally occurring phenomena.
it is undisputed that myriad did not create or alter any of the genetic information encoded in the and genes.the location and order of the nucleotides existed in nature before myriad found them.nor did myriad create or alter the genetic structure of dna.instead,myriad principal contribution was uncovering the precise location and genetic sequence of the and genes within chromosomes and.the question is whether this renders the genes patentable.
myriad recognizes that our decision in chakrabarty is central to this inquiry.brief for respondents.in chakrabarty,scientists added four plasmids to a bacterium,which enabled it to break down various components of crude oil,at,and.the court held that the modified bacterium was patentable.it explained that the patent claim was not to a hitherto unknown natural phenomenon,but to a nonnaturally occurring manufacture or composition of matter a product of human ingenuity having a distinctive name,character and use.at quoting hartranft wiegmann,alteration in original.the chakrabarty bacterium was new with markedly different characteristics from any found in nature,at,due to the additional plasmids and resultant capacity for degrading oil.at.in this case,by contrast,myriad did not create anything.to be sure,it found an important and useful gene,but separating that gene from its surrounding genetic material is not an act of invention.
groundbreaking,innovative,or even brilliant discovery does not by itself satisfy the inquiry.in funk brothers seed kalo inoculant,this court considered a composition patent that claimed a mixture of naturally occurring strains of bacteria that helped leguminous plants take nitrogen fr